Close Menu

NEW YORK – Myriad Genetics is partnering with the University of Leeds Center for Personalized Medicine and Health (LCPMH) to conduct a clinical utility study of the Prolaris prostate cancer test.

Prolaris analyzes the expression of 31 cell cycle genes, and may be combined with prostate specific antigen testing and Gleason score to gauge the aggressiveness of a patient's prostate cancer over the next decade.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.